We are proud to announce that three members of our team have been recognized by Managing IP. Dr. Jacqueline Lui and Ms. Pauli Wong have been recognized as a Patent Star and Mr. Eddie Ho as a Rising Star by ManagingIP. These prestigious awards acknowledge their exceptional expertise and invaluable contributions to the field of intellectual property.

Dr. Lui is widely recognized as a leading expert in patent law, specializing in cross-jurisdiction patent prosecution and strategy. With over 20 years of experience in IP, she has provided invaluable guidance to startups, Fortune 500 companies, and HK/Nasdaq-listed companies. Her expertise encompasses various critical areas, including IP strategy, portfolio management, technology transfer, due diligence, and enforcement. Dr. Lui's exceptional track record and unwavering commitment to excellence have solidified her reputation as a trusted advisor in the field.

Ms. Pauli Wong oversees the patent drafting team at Eagle IP and assists local and international clients with patent prosecution across a wide range of technology fields. She helps clients navigate IP rights, portfolio management, and global filing strategy for innovations in areas like biotechnology, medical devices, and robotics. Pauli is passionate about empowering Hong Kong innovators, leveraging her ability to quickly understand new technologies, meticulous prosecution skills, strategic business acumen, and commitment to client service.

Mr. Eddie Ho is a qualified Chinese Patent Attorney and has quickly amassed extensive experience drafting and prosecuting patent applications in a broad range of areas, including biology, biotechnology, medical devices, diagnostics, material science, engineering, and software. He helps inventors and companies manage and navigate complex patent portfolios and is exceptionally strong at inter-disciplinary technologies.

Let us come together to celebrate this well-deserved accolade for Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho and to recognize their exceptional dedication to the dynamic world of intellectual property.

Our Past Events

Recommended Insights

Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China's Patent Law]

20 February 2019
Major changes are on the horizon for China’s Patent Law, which will see an overhaul in many areas as early as this year (2019). On January 4, 2019, the National People’s Congress in China published the latest draft of the Fourth Amendment to China’s Patent Law. Several draft amendments have been released for public comment […]

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

4 September 2025
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

9 June 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

21 March 2024
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
Top crossarrow-right